The protective effect of hyperbaric oxygen and Ginkgo biloba extract on Aβ25-35-induced oxidative stress and neuronal apoptosis in rats

Behavioural Brain Research

Volumn 242, Issue 1, 2013, Pages 1-8

  Tian, XiaoQiang ^a   Zhang, LiDa ^b   Wang, JingMei ^c   Dai, JianGuo ^d   Shen, ShanShan ^c   Yang, Lin ^a   Huang, PeiLin ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^c THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^d NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

A 25 35; Apoptosis; Ginkgo biloba extract (EGB761); Hyperbaric oxygen (HBO); Oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; CASPASE 3; CASPASE 9; CYTOCHROME C; GINKGO BILOBA EXTRACT; GLUTATHIONE; MALONALDEHYDE; OXYGEN; PROTEIN BAX; SUPEROXIDE DISMUTASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME RELEASE; ESCAPE BEHAVIOR; HIPPOCAMPUS; HYPERBARIC OXYGEN; MALE; MAZE TEST; NERVE CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CYCLIN D1; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HYPERBARIC OXYGENATION; IN SITU NICK-END LABELING; MALE; MAZE LEARNING; MOTOR ACTIVITY; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; TIME FACTORS;

EID: 84872194706     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.12.026     Document Type: Article

References (65)

1. Yankner B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 1996, 16(5):921-932.
2. Lobo A., Launer L.J., Fratiglioni L., Andersen K., Di Carlo A., Breteler M.M., et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology 2000, 54(11 Suppl. 5):S4-S9.
3. Meyer-Luehmann M., Spires-Jones T.L., Prada C., Garcia-Alloza M., de Calignon A., Rozkalne A., et al. Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer's disease. Nature 2008, 451(7179):720-724.
4. Pike C.J., Walencewicz A.J., Glabe C.G., Cotman C.W. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Research 1991, 563(1-2):311-314.
5. Butterfield D.A., Castegna A., Lauderback C.M., Drake J. Evidence that amyloid betapeptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiology of Aging 2002, 23(5):655-664.
6. Paulson J.B., Ramsden M., Forster C., Sherman M.A., McGowan E., Ashe K.H. Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease. American Journal of Pathology 2008, 173(3):762-772.
7. Shalova I.N., Cechalova K., Rehakova Z., Dimitrova P., Ognibene E., Caprioli A., et al. Decrease of dehydrogenase activity of cerebral glyceraldehyde-3-phosphate dehydrogenase in different animal models of Alzheimer's disease. Biochimica et Biophysica Acta 2007, 1770(5):826-832.
8. Pratico D., Clark C.M., Liun F., Virginia Y., Lee M., Trojanowski J.Q. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Archives of Neurology 2002, 59(6):972-976.
9. Butterfield D.A., Koppal T., Subramaniam R., Vitamin Yatin S. E as an antioxidant/free radical scavenger against amyloid beta-peptide-induced oxidative stress in neocortical synaptosomal membranes and hippocampal neurones in culture: insights into Alzheimer's disease. Reviews in the Neurosciences 1999, 10(2):141-149.
10. Lovell M.A., Ehmann W.D., Butler S.M., Markesbery W.R. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 1995, 45(8):1594-1601.
11. Markesbery W.R., Carney J.M. Oxidative alterations in Alzheimer's disease. Brain Pathology 1999, 9(1):133-146.
12. Devi L., Prabhu B.M., Galati D.F., Avadhani N.G., Anandatheerthavarada H.K. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. Journal of Neuroscience 2006, 26(35):9057-9068.
13. Gibson G.E., Sheu K.F., Blass J.P. Abnormalities of mitochondrial enzymes in Alzheimer disease. Journal of Neural Transmission 1998, 105(8-9):855-870.
14. Maurer I., Zierz S., Moller H.J. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiology of Aging 2000, 21(3):455-462.
15. Smith M.A., Perry G., Richey P.L., Sayre L.M., Anderson V.E., Beal M.F., et al. Oxidative damage in Alzheimer's. Nature 1996, 382(6587):120-121.
16. Reddy P.H. Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. Experimental Neurology 2009, 218(2):286-292.
17. Wang J., Xiong S., Xie C., Markesbery W.R., Lovell M.A. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. Journal of Neurochemistry 2005, 939(4):53-962.
18. DeFeudis F.V., Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Current Drug Targets 2000, 1(1):25-58.
19. Topic B., Tani E., Tsiakitzis K., Kourounakis P.N., Dere E., Hasenöhrl R.U., et al. Enhanced maze performance and reduced oxidative stress of chronic treatment by combined extracts of Zingiber Officinale and Ginkgo Biloba in the aged rat. Neurobiology of Aging 2002, 23(1):135-143.
20. Yang S.F., Yang Z.Q., Wu Q., Sun A.S., Huang X.N., Shi J.S. Protective effect and mechanism of Ginkgo biloba leaf extracts for Parkinson disease induced by 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine. Acta Pharmacologica Sinica 2001, 22(12):1089-1093.
21. Bastianetto S., Zheng W.H., Quirion R. The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: involvement of its flavonoid constituents and protein kinase C. Journal of Neurochemistry 2000, 74(6):2268-2277.
22. Bastianetto S., Ramassamy C., Dore S., Christen Y., Porier J., Quirion R. The Ginkgo biloba extract (EGB761) protects hippocampal neurons against cell death induced by β-amyloid. European Journal of Neuroscience 2000, 12(6):1882-1890.
23. Mortensen C.R. Hyperbaric oxygen therapy. Current Anaesthesia & Critical Care 2008, 19:333-337.
24. Lina H.C., Wan F.J., Wu C.C., Tunc C.S., Wu T.H. Hyperbaric oxygen protects against lipopolysaccharide-stimulated oxidative stress and mortality in rats. European Journal of Pharmacology 2005, 508(1-3):249-254.
25. Lia J., Liub W., Dinga S., Xu W., Guan Y., Zhang J.H., et al. Hyperbaric oxygen preconditioning induces tolerance against brain ischemia-reperfusion injury by upregulation of antioxidant enzymes in rats. Brain Research 2008, 1210:223-229.
26. Palzur E., Zaaroor M., Vlodavsky E., Milman F., Soustiel J.F. Neuroprotective effect of hyperbaric oxygen therapy in brain injury is mediated by preservation of mitochondrial membrane properties. Brain Research 2008, 1221:126-133.
27. Watson C., Paxinos F. The rat brain in stereotaxic coordinates 2000, Academic Press, U.S., p. 98-102.
28. Xu Y., Hou X.Y., Liu Y., Zong Y.Y. Different protection of K252a and N-acetyl-l-cysteine against amyloid-beta peptide-induced cortical neuron apoptosis involving inhibition of MLK3-MKK7-JNK3 signal cascades. Journal of Neuroscience Research 2009, 87(4):918-927.
29. Pérez-Severiano F., Salvatierra-Sanchez R., Rodriguez-Perez M., Cuevas-Martinez E.Y., Guevara J., Limón D., et al. S-Allylcysteine prevents amyloid-beta pep-tide-induced oxidative stress in rat hippocampus and ameliorates learning deficits. European Journal of Pharmacology 2004, 89(3):197-202.
30. Klementiev B., Novikova T., Novitskaya V., Walmod P.S., Dmytriyeva O., Pakkenberg B., et al. A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Aβ25-35. Neuroscience 2007, 145(1):209-224.
31. Stepanichev M.Y., Zdobnova I.M., Zarubenko I.I., Moiseeva Y.V., Lazareva N.A., Onufriev M.V., et al. Amyloid-β(25-35)-induced memory impairments correlate with cell loss in rat hippocampus. Physiology & Behavior 2004, 80(5):647-655.
32. Huang J.H., Huang X.H., Chen Z.Y., Zheng Q.S., Sun R.Y. Dose conversion among different animals and healthy volunteers in pharmacological study. Chinese Journal of Clinical Pharmacology 2004, 9(6):1069-1072.
33. Fraser P.E., Lévesque L., McLachlan D.R. Alzheimer beta-amyloid forms an inhibitory neuronal substrate. Journal of Neurochemistry 1994, 62(3):1227-1230.
34. Galani R., Weiss I., Cassel J.C., Kelche C. Spatial memory, habituation, and reactions to spatial and nonspatial changes in rats with selective lesions of the hippocampus, the entorhinal cortex or the subiculum. Behavioural Brain Research 1998, 96(2):1-12.
35. Ilhan N., Halifeoglu I., Ozercan H.I., Ilhan N. Tissue malondialdehyde and adenosine triphosphatase level after experimental liver ischaemia-reperfusion damage. Cell Biochemistry and Function 2001, 19(3):207-212.
36. Ré D.B., Boucraut J., Samuel D., Birman S., Kerkerian-Le Goff L., Had-Aissouni L. Glutamate transport alteration triggers differentiation-state selective oxidative death of cultured astrocytes: a mechanism different from excitotoxicity depending on intracellular GSH contents. Journal of Neurochemistry 2003, 85(5):1159-1170.
37. Pomara N., Sidtis J.J. Alzheimer's disease. New England Journal of Medicine 2010, 362(19):1844-1845.
38. Kraus B., Wolff H., Heilmann J., Elstner E.F. Influence of Hypericum perforatum extract and its single compounds on amyloid-beta mediated toxicity in microglial cells. Life Sciences 2007, 81(11):884-894.
39. Uberti D., Bianchi I., Olivari L., Ferrari-Toninelli G., Canonico P., Memo M. Pramipexole prevents neurotoxicity induced by oligomers of beta-amyloid. European Journal of Pharmacology 2007, 569(3):194-196.
40. Hauptmann S., Scherping I., Dröse S., Brandt U., Schulz K.L., Jendrach M., et al. Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiology of Aging 2009, 30(10):1574-1586.
41. Fu Y.J., Xiong S., Lovell M.A., Lynn B.C. Quantitative proteomic analysis of mitochondria in aging PS-1 transgenic mice. Cellular and Molecular Neurobiology 2009, 29(5):649-664.
42. Reddy P.H., Beal M.F. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends in Molecular Medicine 2008, 14(2):45-53.
43. Zola-Morgan S., Squire L.R., Amaral D.G. Human amnesia and the medial temporal region: enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus. Journal of Neuroscience 1986, 6(10):2950-2967.
44. Bussière T., Giannakopoulos P., Bouras C., Perl D.P., Morrison J.H., Hof P.R. Progressive degeneration of nonphosphorylated neurofilament protein-enriched pyramidal neurons predicts cognitive impairment in Alzheimer's disease: stereologic analysis of prefrontal cortex area 9. Journal of Comparative Neurology 2003, 463(3):281-302.
45. Butterfield D.A., Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid-peptide associated free radical oxidative stress. Free Radical Biology and Medicine 2002, 32(11):1050-1060.
46. Manczak M., Anekonda T.S., Henson E., Park B.S., Quinn J., Reddy P.H. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Human Molecular Genetics 2006, 15(9):1437-1449.
47. Stepanichev M.Y., Zdobnova I.M., Zarubenko I.I., Moiseeva Y.V., Lazareva N.A., Onufriev M.V., et al. Amyloid-h(25-35)-induced memory impairments correlate with cell loss in rat hippocampus. Physiology and Behavior 2004, 80(5):647-655.
48. Calvert J.W., Zhou C., Nanda A., Zhang J.H. Effect of hyperbaric oxygen on apoptosis in neonatal hypoxia-ischemia rat model. Journal of Applied Physiology 2003, 95(5):2072-2080.
49. Narkowicz C.H., Vial J.H., McCartney P. Hyperbaric oxygen therapy increases free radical levels in the blood of humans. Free Radical Research Communications 1993, 19(2):71-80.
50. Ozden T.A., Uzun H., Bohloli M., Toklu A.S., Paksoy M., Simsek G., et al. The effects of hyperbaric oxygen treatment on oxidative and antioxidants levels during liver regeneration in rats. Tohoku Journal of Experimental Medicine 2004, 203(4):253-265.
51. Koca K., Yurttas Y., Yildiz C., Cayci T., Uysal B., Korkmaz A. Effect of hyperbaric oxygen and ozone preconditioning on oxidative/nitrosative stress induced by tourniquet ischemia/reperfusion in rat skeletal muscle. Acta Orthopaedica et Traumatologica Turcica 2010, 44(6):476-483.
52. Mahadevan S., Park Y. Multifaceted therapeutic benefits of Ginkgo bilobal: chemistry, efficacy, safety, and uses. Journal of Food Science 2008, 73(1):14-19.
53. DeFeudis F.V., Papadopoulos V., Drieu K. Ginkgo biloba extracts and cancer: a research area in its infancy. Fundamental and Clinical Pharmacology 2003, 17(4):405-417.
54. Mahady G.B. Ginkgo biloba for the prevention and treatment of cardiovascular disease: a review of the literature. Journal of Cardiovascular Nursing 2002, 16(4):21-32.
55. Song W., Guan H.J., Zhu X.Z., Chen Z.L., Yin M.L., Cheng X.F. Protective effect of bilobalide against nitric oxide-induced neurotoxicity in PC12 cells. Acta Pharmacologica Sinica 2000, 21(4):415-420.
56. Hoerr R. Behavioural and psychological symptoms of dementia (BPSD): effects of EGb 761. Pharmacopsychiatry 2003, 36(Suppl. 1):S56-S61.
57. Maclennan K.M., Darlington C.L., Smith P.F. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Progress in Neurobiology 2002, 67(3):223-257.
58. Li G., Ma R., Huang C., Tang Q., Fu Q., Liu H., et al. Protective effect of erythropoietin on beta-amyloid-induced PC12 cell death through antioxidant mechanisms. Neuroscience Letters 2008, 442(2):143-147.
59. Mullauer F.B., Kessler J.H., Medema J.P. Betulinic acid induces cytochrome c release and apoptosis in a Bax/Bak-independent, permeability transition pore dependent fashion. Apoptosis 2009, 14(2):191-202.
60. Orrenius S. Reactive oxygen species in mitochondria-mediated cell death. Drug Metabolism Reviews 2007, 39(2-3):443-455.
61. Kroemer G., Zamzami N., Susin S.A. Mitochondrial control of apoptosis. Immunology Today 1997, 18(1):44-51.
62. Fan T.J., Han L.H., Cong R.S., Liang J. Caspase family proteases and apoptosis. Acta Biochimica et Biophysica Sinica 2005, 37(11):719-727.
63. Luo Y., Smith J.V., Paramasivam V., Burdick A., Curry K.J., Buford J.P., et al. Inhibition of amyloid-β aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(19):12197-12202.
64. Palzur E., Zaaroor M., Vlodavsky E., Milman F., Soustiel J.F. Neuroprotective effect of HBO therapy in brain injury is mediated by preservation of mitochondrial membrane properties. Brain Research 2008, 1221:126-133.
65. Koh P.O. Gingko biloba extract (EGb 761) prevents increase of Bad-Bcl-XL interaction following cerebral ischemia. American Journal of Chinese Medicine 2009, 37(5):867-876.